How much does domestic Erdafitinib cost?

Erdafitinib (Erdafitinib) is a targeted drug targeting FGFR mutations and is mainly used to treat advanced or metastatic urothelial carcinoma (bladder cancer). For domestic patients, price is a matter of great concern. At present, erdafitinib is still an original drug in the Chinese market, and a domestic version has not yet appeared. Therefore, direct purchase in China faces certain difficulties, and it is not yet included in the scope of medical insurance, which means that patients need to bear all the drug costs themselves. What is available on the market is mainly the original drug from Hong Kong, China. Its price is relatively high, and the monthly treatment cost can reach more than 20,000 yuan, which puts great financial pressure on patients and families.

In contrast, the foreign generic drug market provides some more price-competitive options. For example, the Lao and Bangladeshi versions of generic erdafitinib drugs range in price from a few hundred to 2,000 yuan. These generic drugs are basically the same as the original drugs in terms of ingredients and can achieve similar therapeutic effects, but attention must be paid to the legality and quality control of the drug source. When patients choose generic drugs, they usually refer to the registration certification and manufacturer's qualifications to ensure that the drugs are safe and reliable.

In addition, the price of erdafitinib is affected by the dosage and medication cycle. Standard treatment regimens require dosage adjustments based on patient weight, disease progression, and individual tolerance, so the actual cost of medication will vary for each patient. Although the price is higher, as a targeted therapy drug, erdafitinib can accurately intervene in abnormal FGFR signaling pathways and improve disease control and quality of life. For patients with specific molecular abnormalities, its value is significantly higher than traditional chemotherapy drugs.

To sum up, domestically produced erdafitinib has not yet been launched on the market, and the price for patients to obtain the original drug domestically is relatively high, while overseas generic drugs provide a relatively economical choice. When considering medication options, patients should reasonably evaluate the cost of treatment based on their financial capabilities, legality of drug sources, and physician recommendations to ensure safe, effective, and sustainable long-term treatment.

Reference materials：https://www.balversa.com/